AstraZeneca: Farxiga meets all endpoints in late-stage trial
(CercleFinance.com) - AstraZeneca said on Tuesday that its diabetes drug Farxiga has achieved all its primary and secondary endpoints in a Phase 3 trial with patients with chronic kidney disease.
The study showed that Farxiga significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease, both with and without type-2 diabetes, the drugmaker said in a statement.
The trial also met all its secondary endpoints in patients with and without type-2 diabetes, making Farxiga the first medicine to significantly reduce the risk of death from any cause in this population.
Chronic kidney disease affects nearly 700 million people worldwide, many of whom are still undiagnosed.
There are currently limited treatment options for these patients, who present significant morbidity and an increased risk of heart failure and premature death.
The company's shares were up 0.7% in early morning trading. They have risen over 12% so far this year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The study showed that Farxiga significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease, both with and without type-2 diabetes, the drugmaker said in a statement.
The trial also met all its secondary endpoints in patients with and without type-2 diabetes, making Farxiga the first medicine to significantly reduce the risk of death from any cause in this population.
Chronic kidney disease affects nearly 700 million people worldwide, many of whom are still undiagnosed.
There are currently limited treatment options for these patients, who present significant morbidity and an increased risk of heart failure and premature death.
The company's shares were up 0.7% in early morning trading. They have risen over 12% so far this year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.